GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results for GSK
1,651.00
+8.50 (0.52%)
Apr 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,640.00 - 1,661.18
52 week 1,528.00 - 2,076.00
Open 1,652.00
Vol / Avg. 6.74M/7.98M
Mkt cap 80.23B*
P/E 14.86
Div/yield 23.00/4.72*
EPS 1.11*
Shares 4.86B
Beta     -
Inst. own     -
*GBP
Jul 23, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
May 7, 2014
GlaxoSmithKline PLC Annual General Meeting - 2:30PM GMT+1 - Add to calendar
Apr 30, 2014
Q1 2014 GlaxoSmithKline PLC Earnings Conference Call - 2:00PM GMT+1 - Add to calendar
Apr 30, 2014
Q1 2014 GlaxoSmithKline PLC Earnings Release - 12:00PM GMT+1 - Add to calendar
Mar 4, 2014
GlaxoSmithKline at Cowen Health Care Conference
Mar 4, 2014
GlaxoSmithKline at Credit Suisse Healthcare Conference
Feb 24, 2014
GlaxoSmithKline at Citi Global Healthcare Conference
Feb 5, 2014
Q4 2013 GlaxoSmithKline Earnings Conference Call
Feb 5, 2014
Q4 2013 GlaxoSmithKline PLC Earnings Release
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 36.27% 21.23%
Operating margin 39.01% 27.58%
EBITD margin - 34.40%
Return on average assets 24.15% 13.47%
Return on average equity 152.20% 84.96%
Employees 99,817 -
CDP Score - 98 A

Address

C8 Gsk House, 980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 48
Simon Dingemans Chief Financial Officer, Executive Director
Age: 49
Moncef Slaoui Chairman - Research & Development, Executive Director
Age: 53
Deirdre P. Connelly President - North American Pharmaceuticals
Roger Connor President - Global Manufacturing & Supply
Marc Dunoyer Chairman - GSK Japan, Global Head - GSK Rare Diseases
Shah Abbas Hussain President - Europe & EMAP
Age: 47
Patrick Vallance President - Pharmaceuticals R&D
Emma Walmsley President - Consumer Healthcare Worldwide
Christophe Weber President - Vaccines